Cutting-edge

Mutation-agnostic vaccine for flu and COVID19

Novel Product

VaxDome technology delivers a low dose of the virus in combination with a viral propagation inhibitor that allows sequestration of the virus and training of the immune system to prevent infection. Broad, cross-viral immunity is developed.

=

+

Zanamivir
(binds to NA)

Influenza

zIFV

Packaged in an easy-to-use intranasal syringe

HA

NA

HA - Hemagglutinin
NA - Neuraminidase

Novel Mechanism

zIFV blocks influenza entry and release and sequesters virus within cells

Normal infection process

zIFV infection

zIFV immunization generates tertiary lymphoid structures in lung tissue
zIFV infection only requires 10 infectious units per dose for immunization